The general office of the General Administration of the people's Republic of China solicits public opinions on the announcement on matters related to drug re registration (Draft for comments)
-
Last Update: 2017-02-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: on February 24, 2017, in order to implement the relevant requirements of the opinions of the State Council on the reform of the review and approval system for pharmaceutical and medical devices (GF [2015] No 44), the State Food and Drug Administration drafted the announcement on matters related to drug re registration (Draft for comments), which is now open to the public for comments Please send the modification comments to the State Food and drug administration by email before April 13, 2017 Email: hxypc@cfda.gov.cn Annex: Announcement on matters related to drug re registration (Draft for comments) General Office of food and Drug Administration February 13, 2017 Annex: Announcement on matters related to drug re registration (Draft for comments) Docx
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
